Can variants in EPHX2, CYP4F2, PTGS2, and MBOAT7 shift lipid signaling toward inflammation?

Clinical and effectiveness evidence

Genetic variations in EPHX2, CYP4F2, PTGS2, and MBOAT7 directly alter the synthesis, metabolism, and membrane storage of key lipid mediators, shifting the physiological balance toward heightened inflammation or delayed resolution.

• EPHX2 and vascular inflammation: The functional EPHX2 missense variant rs751141 (Arg287Gln) alters soluble epoxide hydrolase (sEH) activity. The GG genotype preserves high sEH activity, rapidly degrading protective epoxyeicosatrienoic acids (EETs) into diols (DHETs). This depletion of anti-inflammatory EETs correlates with increased risks of hypertension, accelerated diabetic nephropathy, and early neurological deterioration following ischemic stroke. Conversely, the AA genotype reduces sEH activity to 25–58% of wild-type levels, preserving EETs and limiting vascular injury.
• CYP4F2 and vascular tone: The CYP4F2 rs2108622 (V433M) loss-of-function variant reduces the synthesis of 20-hydroxyeicosatetraenoic acid (20-HETE) to roughly 56–66% of wild-type levels. This disruption of 20-HETE and associated vitamin K/E pathways is clinically associated with elevated risks for hypertension, ischemic stroke, and metabolic syndrome.
• PTGS2 and inflammatory reactivity: The PTGS2 (COX-2) promoter variant rs20417 (−765G>C) disrupts an Sp1 binding site and creates an E2F site, directly altering inducible transcription. In conditions like asthma, the rs20417 CC genotype can lead to a more than tenfold increase in the production of prostaglandin E₂ (PGE₂) and D₂ (PGD₂), generating a hyper-inflammatory state.
• MBOAT7 and tissue remodeling: The MBOAT7 rs641738 loss-of-function variant compromises the Lands' cycle, reducing arachidonic acid (AA) sequestration in membranes. The resulting excess of free AA feeds pro-inflammatory cascades, promoting chronic tissue inflammation, steatosis, and fibrogenesis.

Mechanistic explanations

These genetic polymorphisms alter lipid signaling through distinct molecular pathways:

• Epoxide hydrolysis (EPHX2): Modulates the ratio of active EETs—which suppress oxidative stress and promote vasodilation—to their inactive diol metabolites (DHETs).
• Omega-hydroxylation (CYP4F2): Impairs the conversion of AA into 20-HETE, a potent regulator of renal sodium excretion and microvascular tone.
• Prostanoid synthesis (PTGS2): Alters the rate-limiting conversion of free AA into prostaglandin H₂ (PGH₂), shifting the downstream balance of prostanoids and disrupting the metabolic transitions required to synthesize specialized pro-resolving mediators.
• Lysophospholipid acyltransferase activity (MBOAT7): Impairs the transfer of arachidonoyl-CoA to lysophosphatidylinositol (LPI). This defect decreases membrane phosphatidylinositol (specifically PI 38:4) and causes free AA to accumulate, while also impairing autophagy and lysosomal membrane stability.

Bottom line

Variants in EPHX2, CYP4F2, PTGS2, and MBOAT7 functionally alter the enzymatic machinery governing eicosanoid and phospholipid biology. By modifying the availability of free arachidonic acid, the synthesis of prostanoids and 20-HETE, and the hydrolysis of anti-inflammatory epoxides, these polymorphisms collectively shift the systemic balance toward greater inflammatory reactivity and impaired tissue resolution.